Vol 71, No 5 (2021)
Review paper
Published online: 2021-10-13

open access

Page views 6201
Article views/downloads 408
Get Citation

Connect on Social Media

Connect on Social Media

Pancreatoduodenectomy due to cancer in the older population

Jakub Kenig1, Piotr Richter1
Nowotwory. Journal of Oncology 2021;71(5):321-327.


By 2030, 70% of all pancreatic cancer will be diagnosed in the older population. However, pancreas operations are a complex surgical procedure with a high rate of morbidity and mortality. Therefore, the benefits of surgical resection in older patients are controversial and decisions about treatment for this group must be well balanced. Chronological age alone should not be a contraindication for multimodal radical treatment in older patients. Fit patients, according to the comprehensive geriatric assessment (SGA), should be qualified for the same treatment as younger patients to benefit the same outcomes. However, they should be operated on in high-volume hospitals by experienced surgeons. Prefrail patients should undergo prehabilitation, during neoadjuvant treatment also, and then reevaluated. Frail patients should be discussed in an oncogeriatric meeting. We still do not have evidence-based data to design a tailored approach for them so as to balanced good oncologic outcomes and the appropriate postoperative quality of life.

Article available in PDF format

View PDF Download PDF file


  1. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009; 27(17): 2758–2765.
  2. Rahib L, Smith B, Aizenberg R, et al. Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States. Cancer Research. 2014; 74(11): 2913–2921.
  3. Amin S, Lucas A, Frucht H. Evidence for Treatment and Survival Disparities by Age in Pancreatic Adenocarcinoma. Pancreas. 2013; 42(2): 249–253.
  4. Puts MTE, Santos B, Hardt J, et al. An update on a systematic review of the use of geriatric assessment for older adults in oncology. Ann Oncol. 2014; 25(2): 307–315.
  5. Kamisawa T, Yuyang T, Egawa N, et al. Characteristics of pancreatic carcinoma in the elderly. Int J Pancreatol. 1998; 24(1): 31–34.
  6. Kenig J. Oncogeriatrics (part 1.). Frailty in older adults with cancer. Nowotwory. Journal of Oncology. 2019; 69(2): 55–57.
  7. Loh KP, Soto-Perez-de-Celis E, Hsu T, et al. What Every Oncologist Should Know About Geriatric Assessment for Older Patients With Cancer: Young International Society of Geriatric Oncology Position Paper. J Oncol Pract. 2018; 14(2): 85–94.
  8. Klabunde CN, Ambs A, Keating NL, et al. The role of primary care physicians in cancer care. J Gen Intern Med. 2009; 24(9): 1029–1036.
  9. Grodzicki T, Kenig J. Problemy okołooperacyjne u osób w wieku podeszłym. PZWL Wydawnictwo Lekarskie 2018.
  10. Kenig J, Szabat K. Oncogeriatrics (part 7.). Geriatric assessment for older patients with cancer. Nowotwory. Journal of Oncology. 2020; 70(4): 153–157.
  11. Rostoft S, van Leeuwen B. Frailty assessment tools and geriatric assessment in older patients with hepatobiliary and pancreatic malignancies. Eur J Surg Oncol. 2021; 47(3 Pt A): 514–518.
  12. He W, Zhao H, Chan W, et al. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery. 2015; 158(5): 1226–1234.
  13. Park HM, Park SJ, Han SS, et al. Surgery for elderly patients with resectable pancreatic cancer, a comparison with non-surgical treatments: a retrospective study outcomes of resectable pancreatic cancer. BMC Cancer. 2019; 19(1): 1090.
  14. Marmor S, Burke EE, Virnig BA, et al. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Cancer. 2016; 122(21): 3378–3385.
  15. Baram A, Moaven O, Tan E, et al. Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis. Int J Surg. 2019; 72: 59–68.
  16. Lee DY, Schwartz JA, Wexelman B, et al. Outcomes of pancreaticoduodenectomy for pancreatic malignancy in octogenarians: an American College of Surgeons National Surgical Quality Improvement Program analysis. Am J Surg. 2014; 207(4): 540–548.
  17. Lightner AM, Glasgow RE, Jordan TH, et al. Pancreatic resection in the elderly. J Am Coll Surg. 2004; 198(5): 697–706.
  18. Bathe OF, Levi D, Caldera H, et al. Radical resection of periampullary tumors in the elderly: evaluation of long-term results. World J Surg. 2000; 24(3): 353–358.
  19. Casadei R, Ricci C, Lazzarini E, et al. Pancreatic resection in patients 80 years or older: a meta-analysis and systematic review. Pancreas. 2014; 43(8): 1208–1218.
  20. Mauriello C, Polistena A, Gambardella C, et al. Pancreatic stump closure after pancreatoduodenectomy in elderly patients: a retrospective clinical study. Aging Clin Exp Res. 2017; 29(Suppl 1): 35–40.
  21. Tamirisa NP, Parmar AD, Vargas GM, et al. Relative Contributions of Complications and Failure to Rescue on Mortality in Older Patients Undergoing Pancreatectomy. Ann Surg. 2016; 263(2): 385–391.
  22. Finlayson E, Fan Z, Birkmeyer JD. Outcomes in octogenarians undergoing high-risk cancer operation: a national study. J Am Coll Surg. 2007; 205(6): 729–734.
  23. Hodul P, Tansey J, Golts E, et al. Age is not a contraindication to pancreaticoduodenectomy. Am Surg. 2001; 67: 270–275.
  24. Ito Y, Kenmochi T, Irino T, et al. The impact of surgical outcome after pancreaticoduodenectomy in elderly patients. World J Surg Oncol. 2011; 9: 102.
  25. Bathe OF, Levi D, Caldera H, et al. Radical resection of periampullary tumors in the elderly: evaluation of long-term results. World J Surg. 2000; 24(3): 353–358.
  26. Delitto D, Luckhurst CM, Black BS, et al. Oncologic and Perioperative Outcomes Following Selective Application of Laparoscopic Pancreaticoduodenectomy for Periampullary Malignancies. J Gastrointest Surg. 2016; 20(7): 1343–1349.
  27. Chapman BC, Gajdos C, Hosokawa P, et al. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Surg Endosc. 2018; 32(5): 2239–2248.
  28. Meng L, Xia Q, Cai Y, et al. Impact of Patient Age on Morbidity and Survival Following Laparoscopic Pancreaticoduodenectomy. Surg Laparosc Endosc Percutan Tech. 2019; 29(5): 378–382.
  29. Zhu J, Wang G, Du P, et al. Minimally Invasive Pancreaticoduodenectomy in Elderly Patients: Systematic Review and Meta-Analysis. World J Surg. 2021; 45(4): 1186–1201.
  30. Arvaniti M, Danias N, Theodosopoulou E, et al. Quality of Life Variables Assessment, Before and After Pancreatoduodenectomy (PD): Prospective Study. Glob J Health Sci. 2015; 8(6): 203–210.
  31. Park JW, Jang JY, Kim EJ, et al. Effects of pancreatectomy on nutritional state, pancreatic function and quality of life. Br J Surg. 2013; 100(8): 1064–1070.
  32. Lindkvist B, Phillips ME, Domínguez-Muñoz JE. Clinical, anthropometric and laboratory nutritional markers of pancreatic exocrine insufficiency: Prevalence and diagnostic use. Pancreatology. 2015; 15(6): 589–597.
  33. Bye A, Jordhøy MS, Skjegstad G, et al. Symptoms in advanced pancreatic cancer are of importance for energy intake. Support Care Cancer. 2013; 21(1): 219–227.
  34. Diouf M, Filleron T, Pointet AL, et al. Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. Qual Life Res. 2016; 25(7): 1713–1723.
  35. Cloyd JM, Tran Cao HS, Petzel MQB, et al. Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. J Surg Oncol. 2017; 115(2): 144–150.
  36. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012; 30(17): 2036–2038.
  37. European Society of Medical Oncology. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2015. http://www.esmo.org/Guidelines/Gastrointestinal-Cancers/Cancer-of-the-Pancreas.
  38. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines Pancreatic Adenocarcinoma (Version 2.2017). https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#pancreatic.
  39. Higuera O, Ghanem I, Nasimi R, et al. Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016; 22(2): 764–775.
  40. Parmar AD, Vargas GM, Tamirisa NP, et al. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014; 156(2): 280–289.
  41. Macchini M, Chiaravalli M, Zanon S, et al. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. Cancer Treat Rev. 2019; 72: 1–6.
  42. Nagrial AM, Chang DK, Nguyen NQ, et al. Australian Pancreatic Cancer Genome Initiative. Adjuvant chemotherapy in elderly patients with pancreatic cancer. Br J Cancer. 2014; 110(2): 313–319.
  43. Marmor S, Burke EE, Virnig BA, et al. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Cancer. 2016; 122(21): 3378–3385.
  44. Lim KH, Chung E, Khan A, et al. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012; 17(2): 192–200.
  45. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis. Lancet Oncol. 2013; 14(11): 1095–1103.
  46. Miura J, Krepline A, Duelge K, et al. Neoadjuvant therapy for pancreatic cancer in patients older than age 75. J Clin Oncol. 2014; 32(3_suppl): 287–287.
  47. Conroy T, Desseigne F, Ychou M, et al. Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19): 1817–1825.
  48. Aldoss I, Tashi T, Gonsalves W, et al. Role of chemotherapy in the very elderly patients with metastatic pancreatic cancer — A Veterans Affairs Cancer Registry analysis. J Geriatr Oncol. 2011; 2(3): 209–214.
  49. Higuera O, Ghanem I, Nasimi R, et al. Management of pancreatic cancer in the elderly. World J Gastroenterol. 2016; 22(2): 764–775.
  50. Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer cachexia. Crit Rev Oncol Hematol. 2013; 88(3): 625–636.
  51. Torgerson S, Wiebe LA. Supportive care of the patient with advanced pancreatic cancer. Oncology (Williston Park). 2013; 27(3): 183–190.
  52. Matsuda Y, Shimakura K, Akamatsu T. Factors affecting the patency of stents in malignant biliary obstructive disease: univariate and multivariate analysis. Am J Gastroenterol. 1991; 86(7): 843–849.
  53. Jeurnink SM, van Eijck CHJ, Steyerberg EW, et al. Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol. 2007; 7: 18.

Nowotwory. Journal of Oncology